Document is current
Any future updates will be listed below
-
Authors
Kizhakeyil, Atish
Zaini, Nurmahirah Binte Mohammed
Poh, Zhi Sheng
Wong, Brandon Han Siang
Loh, Xinpeng
Ng, Aik Seng
Low, Zun Siong
Prasannan, Praseetha
Gong, Chun
Tan, Michelle Guet Khim
Nagarajan, Chandramouli
Huang, Dachuan
Lu, Pang Wan
Lim, Jing Quan
Barrans, Sharon
Ong, Choon Kiat
Lim, Soon Thye
Chng, Wee Joo
Follows, George
Hodson, Daniel J.
Du, Ming Qing
Goh, Yeow Tee
Tan, Suat Hoon
Grigoropoulos, Nicholas Francis
Verma, Navin Kumar https://orcid.org/0000-0002-5940-6633
-
Funding
Funding for this research was provided by:
nanyang technological university (L0412290)
ministry of education - singapore (MOE2017-T2-2-004)
national medical research council (OFLCG18May-0028, NMRC/TA/0051/2016)
addenbrooke's charitable trust, cambridge university hospitals
kay kendall leukaemia fund (KKL649)
medical research council (MR/M008584/1)
wellcome trust (203151/Z/16/Z)
cancer research uk (A25117)
- License Information
-
More Information
Article History
Received: 27 July 2021
Accepted: 24 September 2021
First Online: 16 October 2021
Declarations
:
: The study with patient tumor samples was approved by the ethics review board of Cambridge University Hospitals NHS Foundation Trust (05/Q1604/10) and conducted in accordance with the Declaration of Helsinki. Experiments utilizing primary lymphocytes were approved by the Nanyang Technological University Singapore Institutional Review Board (IRB-2018-05-034 and IRB-2014-09-007) and the SingHealth Central Institutional Review Board (201506–0069). Animal experiments were approved by the SingHealth Institutional Animal Care and Use Committee (IACUC No: 2016/SHS/1231).
: All authors give consent for the publication of manuscript in Molecular Cancer.
: The authors declare that they have no competing interests.
